Orsini

Apr 01, 2025

Orsini Selected as the Exclusive Specialty Pharmacy for Cell Therapy ENCELTO(TM)

Jan 14, 2025

Orsini the Exclusive Specialty Pharmacy Provider for Gene Therapy KEBILIDI(TM) (eladocagene exuparvovec-tneq)

Jan 07, 2025

Orsini and PicnicHealth Partner to Improve Rare Disease Patient Care and Real-World Study Execution

Nov 25, 2024

Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY(TM) (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis

Nov 14, 2024

Orsini Now Distributing CASGEVY® (exagamglogene autotemcel), a Gene-Editing Therapy

Nov 05, 2024

Orsini Now a Specialty Pharmacy Provider for SAJAZIR(TM) (icatibant) Injection, to Treat Acute HAE Attacks

Oct 21, 2024

Orsini Is Now a Specialty Pharmacy Provider for FUROSCIX® (furosemide injection), an Infused Diuretic for Congestive Heart Failure

Oct 03, 2024

Orsini Launches ORBIT(TM) (Orsini Rare Business Intelligence Technology) to Enhance Rare Disease Patient Care

Sep 24, 2024

Orsini Chosen as the Exclusive Specialty Pharmacy Provider for MIPLYFFA(TM) (arimoclomol), the First FDA-Approved Treatment for Niemann-Pick Disease Type C

Aug 15, 2024

Orsini Now Dispensing Livdelzi (seladelpar), for Treatment of Rare Liver Disease

Jun 18, 2024

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders